Skip to main content

Advertisement

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Fig. 1

PARP inhibitor olaparib combined with WEE1/PLK1 dual inhibitor AZD1775 further reduces growth in GC cells. a-c MKN45 and AGS cells were treated with either olaparib or AZD1775 alone for 48 h in a dose-dependent manner. Protein extracts were probed with antibodies against WEE1 and PLK1 and CCK-8 assays were performed. d and e After exposure to 0.3 μM AZD1775 with/without 20 μM olaparib for 48 h, CCK-8 assays and immunoblots were performed in MKN45 and AGS cells. AZD, AZD1775; Ola, olaparib; Com, Combination. Data expressed as Mean ± SD and representative of three independent experiments. *, P < 0.05 by ANOVA analysis

Back to article page